Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
Across >8000 patients treated with single-agent ICI, and within individual cancer types with sufficient power, elevated TMB based on the FDA-approved CDx was associated with more favorable rwOS compared with similar patients with lower TMB levels. This biomarker deserves further clinical investigation to potentially guide the use of immunotherapy in expanded clinical contexts.
Authors
- Amit Mahipal (ORCID: https://orcid.org/0000-0002-1111-8333)
- David Fabrizio (ORCID: https://orcid.org/0000-0001-8088-9476)
- Sarah Sammons (ORCID: https://orcid.org/0000-0003-2589-9422)
- Shilpa Gupta (ORCID: https://orcid.org/0000-0002-8775-503X)
- Miles C. Andrews (ORCID: https://orcid.org/0000-0003-1231-8641)
- Ryon P. Graf (ORCID: https://orcid.org/0000-0002-8065-4148)
- Richard S.P. Huang (ORCID: https://orcid.org/0000-0001-8395-5168)
- David R. Gandara (ORCID: https://orcid.org/0000-0003-1784-048X)
- Lilia Bouzit
- Vivek Subbiah (ORCID: https://orcid.org/0000-0002-6064-6837)
- Gerald Li (ORCID: https://orcid.org/0000-0002-5617-6262)
- Geoffrey R. Oxnard (ORCID: https://orcid.org/0000-0003-1054-8240)
- Megan M. Price
- David P. Carbone (ORCID: https://orcid.org/0000-0003-3002-1921)
- Júlia C.F. Quintanilha (ORCID: https://orcid.org/0000-0001-6908-4474)
- Ramez N. Eskander (ORCID: https://orcid.org/0000-0002-2101-1935)
- Samuel Jacob Klempner (ORCID: https://orcid.org/0000-0002-4062-0808)
- Jonathan Wesley Riess (ORCID: https://orcid.org/0000-0001-7370-7304)
- Jeremy Snider (ORCID: https://orcid.org/0000-0002-2117-7038)
- Cheryl Cho-Phan
- Jeffrey S. Ross (ORCID: https://orcid.org/0000-0001-8494-2596)
- Neeraj Agarwal (ORCID: https://orcid.org/0000-0003-1076-0428)
Institutions
- Boston Medical Center (US)
- Cleveland Clinic (US)
- University of Utah (US)
- UC San Diego Health System (US)
- Huntsman Cancer Institute (US)
- The Ohio State University Wexner Medical Center (US)
- Massachusetts General Hospital (US)
- Sarah Cannon (US)
- Dana-Farber Cancer Institute (US)
- University Hospitals Seidman Cancer Center (US)
- Flatiron Health (United States) (US)
- UC Davis Comprehensive Cancer Center
- The Ohio State University (US)
- Monash University (AU)
- University of California, Davis (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/jitc-2024-010311
- Citations
- 29
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 30.32
Funders
- Flatiron Health
- Foundation Medicine